Acute Lymphoblastic Leukemia Market
Acute Lymphoblastic Leukemia Market by Cell Type (B-Cell and T-Cell Leukemia), by Treatment (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy and Stem Cell Transplantation), by End-User - Industry Size, Share, Global Trends, Competitive Analysis and Forecast, 2019 to 2025
Acute lymphoblastic/lymphocytic leukemia is one of the most common type of cancers that mainly affects children. There are two types of acute lymphocytic leukemia; B-cell type and T-cell type, that can be treated by radiation therapy, chemotherapy, targeted therapy, and others. The global acute lymphocytic leukemia market is expected to witness considerable growth during the forecast period. Increasing prevalence of acute lymphoblastic leukemia is encouraging the players in the market to develop innovative treatments to cure such diseases; thereby, contributing to the growth of the market. According to the National Cancer Institute in 2017, the number of new cases of acute lymphoblastic leukemia in the US was around 1.7 per 100,000 population. With the increasing cases of acute lymphoblastic leukemia, the market players are focusing more on clinical trials, which is expected to fuel the market growth in the near future.
The acute lymphoblastic leukemia market is segmented on the basis of cell type, treatment, and end-user. The market on the basis of cell type is bifurcated into B-cell type and T-Cell type. B-cell type segment is expected to contribute significantly to the growth of the market as 75% of acute lymphoblastic leukemia cases in adults develop from precursors of the B-cell lineage in the US, according to the National Institute of Health in 2017. As per treatment, the market is segmented into chemotherapy, radiation therapy, targeted therapy, immunotherapy, and stem cell transplantation. Among these, chemotherapy is expected to hold significant share in the global acute lymphoblastic leukemia market.
Geographically, the global acute lymphoblastic leukemia market is segmented into North America, Europe, Asia-Pacific and Rest of the World. North America is expected to lead the market in 2018 owing to increasing cases of acute lymphoblastic leukemia. Moreover, the presence of key players that uses T-cell receptors for the development of new drugs and therapy is further supporting the market growth in the region. Europe is the expected to follow North America in terms of revenue generation due to the technological advancements in the biotechnology domain.
There are various companies involved in the development of treatments and therapies for acute lymphoblastic leukemia market which includes Pfizer, Inc., Spectrum Pharmaceuticals Inc., Novartis AG, Hoffmann La Roche Ltd., Celgene Corp., Thermo Fisher Scientific, Inc., Eli Lilly & Co., Lonza Group Ltd., and many others. Novartis AG is one of the leading players operating in the global acute lymphoblastic leukemia market. The strong foothold of the company is attributed to its strong geographical presence and robust product line. Further, the approval by the government authorities for its products also aids in enhancing its existing product line. For instance, in October 2017, tisagenlecleucel (KYMRIAH) received FDA approval for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia. With this approval, the company has successfully strengthened its existing product portfolio.
Research Methodology:
The market study of the acute lymphoblastic leukemia market is incorporated by extensive primary and secondary research conducted by a research team at OMR. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.
Secondary Sources Include:
- Financial reports of companies involved in the market
- Authentic Public Databases such as the National Institute of Health, the American Cancer Society, World Cancer Research Fund and others
- Whitepapers, research-papers and news blogs
- Company websites and their product catalog
The report is intended for research organizations, biotechnology and pharmaceutical companies, investment companies, potential entrants, venture capitalists, academic and research institutes, and government organizations for overall market analysis and competitive analysis. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.
Market Segmentation:
- Global Acute lymphoblastic leukemia Market Research and Analysis by CellType.
- Global Acute lymphoblastic leukemia Market Research and Analysis by Treatment.
- Global Acute lymphoblastic leukemia Market Research and Analysis by End-user.
The Report Covers:
- Comprehensive research methodology of the acute lymphoblastic leukemia market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global acute lymphoblastic leukemia market.
- Insights about market determinants which are stimulating the global acute lymphoblastic leukemia market.
- Detailed and extensive market segments with regional distribution of forecast revenues.
- Extensive profiles and recent developments of market players.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules &Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Pfizer, Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Spectrum Pharmaceuticals Inc.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Novartis AG
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Hoffmann-La Roche Ltd.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Celgene Corp.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Acute Lymphoblastic Leukemia Market by Cell Type
5.1.1. B-Cell
5.1.2. T-Cell
5.2. Global Acute Lymphoblastic Leukemia Market by Treatment
5.2.1. Chemotherapy
5.2.2. Radiation Therapy
5.2.3. Targeted Therapy
5.2.4. Immunotherapy
5.2.5. Stem Cell Transplantation
5.3. Global Acute Lymphoblastic Leukemia Market by End-User
5.3.1. Hospitals and Clinics
5.3.2. Research Institutes
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AbbVie, Inc.
7.2. Adaptive Biotechnologies Corp.
7.3. Amgen, Inc.
7.4. AstraZeneca PLC
7.5. Atara Biotherapeutics, Inc.
7.6. Athenex, Inc.
7.7. Baxter International, Inc.
7.8. Blubird Bio, Inc.
7.9. Bristol-Myers Squibb Co.
7.10. Cabaletta Bio, Inc.
7.11. CARsgen Therapeutics Co. Ltd.
7.12. Celgene Corp.
7.13. Daiichi Sankyo Co. Ltd.
7.14. Deciphera Pharmaceuticals LLC
7.15. Eisai Co Ltd.
7.16. Eli Lilly and Co
7.17. Erytech Pharma, SA
7.18. F. Hoffmann-La Roche Ltd.
7.19. Formula Pharmaceuticals, Inc.
7.20. Gamida Cell Ltd.
7.21. Genmab A/S
7.22. ImmunoGen Inc.
7.23. Juno Therapeutics, Inc.
7.24. Kite Pharma, Inc.
7.25. Lonza Group Ltd.
7.26. Medigene AG
7.27. NexImmune Inc.
7.28. Nimbus Therapeutics Inc.
7.29. Nohla Therapeutics, Inc.
7.30. Protheragen, Inc.
7.31. Spectrum Pharmaceuticals, Inc.
7.32. Takeda Pharmaceutical Co. Ltd.
7.33. Thermo Fisher Scientific, Inc.
1. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY CELL TYPE, 2018-2025 ($ MILLION)
2. GLOBAL B-CELL TYPE ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
3. GLOBAL T-CELL TYPE ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
4. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
5. GLOBAL CHEMOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
6. GLOBAL RADIATION THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
7. GLOBAL TARGETED THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
8. GLOBAL IMMUNOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
9. GLOBAL STEM CELL TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
10. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
11. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA IN HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
12. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA IN RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
13. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
14. NORTH AMERICAN ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
15. NORTH AMERICAN ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
16. NORTH AMERICAN ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
17. NORTH AMERICAN ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
18. EUROPEAN ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
19. EUROPEAN ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
20. EUROPEAN ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
21. EUROPEAN ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
22. ASIA-PACIFIC ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
23. ASIA-PACIFIC ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
24. ASIA-PACIFIC ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
25. ASIA-PACIFIC ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
26. REST OF THE WORLD ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
27. REST OF THE WORLD ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
28. REST OF THE WORLD ACUTE LYMPHOBLASTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
1. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SHARE BY TYPE, 2018 VS 2025(%)
2. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SHARE BY TREATMENT, 2018 VS 2025(%)
3. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SHARE BY END-USER, 2018 VS 2025(%)
4. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SHARE BY GEOGRAPHY, 2018 VS 2025(%)
5. US ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, 2018-2025($ MILLION)
6. CANADA ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, 2018-2025($ MILLION)
7. UK ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, 2018-2025($ MILLION)
8. FRANCE ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, 2018-2025($ MILLION)
9. GERMANY ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, 2018-2025($ MILLION)
10. SPAIN ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, 2018-2025($ MILLION)
11. ITALY ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, 2018-2025($ MILLION)
12. ROE ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, 2018-2025($ MILLION)
13. INDIA ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, 2018-2025($ MILLION)
14. CHINA ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, 2018-2025($ MILLION)
15. JAPAN ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, 2018-2025($ MILLION)
16. REST OF ASIA-PACIFIC ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, 2018-2025($ MILLION)
17. REST OF THE WORLD ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, 2018-2025($ MILLION)
